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RIPK1/RIPK3 promotes vascular permeability to allow
tumor cell extravasation independent of its necroptotic
function
Kay Hänggi1, Lazaros Vasilikos1, Aida Freire Valls2,3, Rosario Yerbes2, Janin Knop1, Lisanne M Spilgies1, Kristy Rieck1, Tvisha Misra1,
John Bertin4, Peter J Gough4, Thomas Schmidt3, Carmen Ruiz de Almodòvar2 and W Wei-Lynn Wong*,1
Necroptosis is an inflammatory form of programmed cell death requiring receptor-interacting protein kinase 1, 3 (RIPK1, RIPK3)
and mixed lineage kinase domain-like protein (MLKL). The kinase of RIPK3 phosphorylates MLKL causing MLKL to form a pore-like
structure, allowing intracellular contents to release and cell death to occur. Alternatively, RIPK1 and RIPK3 have been shown to
regulate cytokine production directly influencing inflammatory immune infiltrates. Recent data suggest that necroptosis may
contribute to the malignant transformation of tumor cells in vivo and we asked whether necroptosis may have a role in the tumor
microenvironment altering the ability of the tumor to grow or metastasize. To determine if necroptosis in the tumor
microenvironment could promote inflammation alone or by initiating necroptosis and thereby influencing growth or metastasis of
tumors, we utilized a syngeneic tumor model of metastasis. Loss of RIPK3 in the tumor microenvironment reduced the number of
tumor nodules in the lung by 46%. Loss of the kinase activity in RIPK1, a member of the necrosome also reduced tumor nodules in
the lung by 38%. However, the loss of kinase activity in RIPK3 or the loss of MLKL only marginally altered the ability of tumor cells
to form in the lung. Using bone marrow chimeras, the decrease in tumor nodules in the Ripk3−/− appeared to be due to the stromal
compartment rather than the hematopoietic compartment. Transmigration assays showed decreased ability of tumor cells to
transmigrate through the vascular endothelial layer, which correlated with decreased permeability in the Ripk3−/−mice after tumor
injection. In response to permeability factors, such as vascular endothelial growth factor, RIPK3 null endothelial cells showed
decreased p38/HSP27 activation. Taken together, our results suggest an alternative function for RIPK1/RIPK3 in vascular
permeability leading to decreased number of metastasis.
Cell Death and Disease (2017) 8, e2588; doi:10.1038/cddis.2017.20; published online 2 February 2017
Cell death is considered to be one of the hallmarks of
malignancy – either by upregulation of anti-apoptotic genes or
downregulation or silencing of pro-apoptotic genes.1 Necrop-
tosis is a programmed cell death pathway triggered by tumor
necrosis factor (TNF), Fas, Toll-like receptor ligands and type I
interferon upon loss or inhibition of caspase-8.2–6 Under-
standing whether necroptosis is part of the cell death hallmark
of malignancy has become an area of intense research.
Receptor-interacting protein kinase 1 (RIPK1), a multi-
functional protein that contains an N-terminal Ser/Thr kinase
domain, is known to be a critical regulator at the decision point
of cytokine induced NF-kB activation for survival or cell death
by either apoptosis or necroptosis.7 Necroptosis is triggered
by RIPK1 interaction with RIPK3, RIPK3 dimerization,
autophosphorylation of RIPK3 and subsequent phosphoryla-
tion of mixed lineage kinase domain-like protein (MLKL).8–10
Upon phosphorylation, MLKL is believed to form a pore
complex that can compromise cell membrane integrity11,12
resulting in the release intracellular contents. The result is an
inflammatory response to the release of danger-associated
molecular patterns and/or the direct regulation of cytokines by
RIPK1/RIPK3 dimerization.13
Recent evidence suggests RIPK3 is a tumor suppressor.
RIPK3 has been found to be epigenetically silenced in breast
and pancreatic cancer tissue14,15 and in melanoma cell line.16
In tumor models, loss of RIPK3 aided a TAK1-induced
inflammation model of hepatocarcinogenesis,17 whereas loss
of RIPK3 in combination with internal tandem duplication
mutations of FMS-like tyrosine kinase-3 led to an increase in
leukemia in vivo, which was because of the absence of
inflammasome activation.18 Expression of RIPK3 in patient
samples also has been associated with disease outcome. In
cervical cancers, low RIPK3 protein expression in patient
biopsies correlated to a reduced response to PolyIC-based
adjuvant immunotherapeutic approaches.19 In patients suffer-
ing from intestinal bowel disease and presenting with color-
ectal cancer, loss of RIPK3 expression was detected in
neoplastic tissue compared with non-neoplastic and the loss
of expression was correlative to a poor prognosis.20 These
findings suggest a role for RIPK3 and potentially necroptosis
in tumorigenesis, as well as prognosis.
By contrast, the deletion of RIPK1, RIPK3 or MLKL in
breast cancer cell lines reduced the tumorigenic potential of
the cell to form colonies and subcutaneous tumors in
1Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland; 2Biochemistry Center, Heidelberg University, Heidelberg, Germany; 3Department of
General, Visceral and Transplantation Surgery, Heidelberg University, Heidelberg, Germany and 4Pattern Recognition Receptor Discovery Performance Unit, Immuno-
Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, PA, USA
*Corresponding author: WW-L Wong, Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190 Y44 J55, Zurich 8057, Switzerland. Tel: +41 44
635 3720; Fax: +41 44 635 6883; E-mail: wong@immunology.uzh.ch
Received 12.10.16; revised 22.12.16; accepted 03.1.17; Edited by J Zhang
Citation: Cell Death and Disease (2017) 8, e2588; doi:10.1038/cddis.2017.20
Ofﬁcial journal of the Cell Death Differentiation Association
www.nature.com/cddis
immunocompromised mice.21 To add to the complexity,
increased expression in RIPK3, RIPK1 and MLKL was found
in patient pancreatic ductal adenocarcinoma (PDA) compared
with normal tissue and the loss of RIPK3 in a V12K-Ras-
induced PDA model increased survival by reducing the
expression of CXCL-1/Mincle pathway and by altering the
presence of tumor-suppressive immune cell.22 In addition, our
work and others show that RIPK1/RIPK3 drive cytokine
production either in conjunction with initiating necroptosis or
completely independently.23,24 This makes it difficult to
interpret inflammation driven in vivo models of tumorigenesis
in RIPK3-deficient mice.
We sought to differentiate the role of RIPK3 or necroptosis in
tumorigenesis versus the tumor microenvironment by utilizing
syngeneic mouse tumor models. These models can be used
to simulate metastasis, what 90% of cancer patients die from
rather than the primary tumor. Similar to recently published
results, we found the role of RIPK3 in the tumor microenviron-
ment was not because of the altered immune response but the
ability of tumor cells to extravasate into the lung.25 However,
we found the kinase activity of RIPK1 but not RIPK3 kinase
activity was important in the extravasation step of metastasis.
Loss of MLKL showed a reduction but not significant number
of tumor nodules formed in the lung compared with Ripk3−/−.
Our data shows that in addition to the possibility of activating
necroptosis through a death receptor 6-mediated manner as
previously found, RIPK3 has a critical role as signaling platform
downstream of stimuli promoting permeability through p38/
HSP27. These data support the role of RIPK1/RIPK3 as a
signaling platform in promoting vascular permeability required
for tumor cell extravasation.
Results
Loss of RIPK3 results in decreased tumor nodules in the
lung. To determine whether tumor cells were able to form a
solid tumor, Ripk3−/− mice were injected subcutaneously with
B16-F10 cells. In agreement with recently published data,22
solid tumors formed at the same rate and volume in both wild-
type and Ripk3−/− mice (Figure 1a). This suggested the loss
of RIPK3 in the tumor microenvironment did not affect
established tumor cells from growing. To determine if RIPK3
in the tumor microenvironment could have a role in a tumor
metastasis model, B16-F10 tumor cells were injected tail vein
into wild-type mice. Lung homogenates were made 2, 6 and
12 h after tail vein injection and RIPK3 levels were assayed
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Figure 1 Loss of RIPK3 in the tumor microenvironment reduces tumor nodules in the lung in a tumor model of extravasation. (a) Wild-type (Wt) and Ripk3−/− mice were
injected subcutaneously with 1 × 105 B16-F10 tumor cells and tumor size was measured over time (pooled data of n= 2 experiments; 5–7 mice used per group in each
experiment). (b) RIPK3 but not RIPK1 or MLKL protein levels were elevated in total lung lysates of wild-type mice 6 and 12 h after injection of B16-F10 cells shown by
representative immunoblot and corresponding quantification of pixel density from three mice per timepoint. Fold change relative to untreated Wt control is shown from values
normalized to actin (statistical analysis by one-way ANOVA). (c) Tumor nodules were counted 14 days post tail vein injection (dpi) of B16-F10 cells (2 × 105) into Ripk3 littermate
control mice (left panel, n= 1; 3–4 mice used per group) and tumor nodules were counted 14 dpi of B16-F10 cells (2 × 105) intoWt and Ripk3−/− mice (right panel, pooled data
shown of n= 3 experiments; 3–5 mice used per group in each experiment). (d) Corresponding size is shown of tumor nodules classified macroscopically into large (41 mm),
medium (0.5 mm–1 mm) and small (o0.5 mm) shown (pooled, n= 3), and corresponding representative macroscopic pictures of the lungs were shown. (e) Tumor nodules were
counted 20 dpi of MC-38 cells (3 × 105) into Wt and Ripk3−/−mice (n= 1; 6 mice used per group; P= 0.14). Each dot represents a mouse except stated otherwise; statistical
analysis by t-test except stated otherwise. *Po0.05, **Po0.01
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by immunoblotting. After 12 h, the level of RIPK3 protein was
approximately twofold higher (Figure 1b), suggesting a
potential role for RIPK3 in tumor formation in the lung.
Interestingly, no changes in RIPK1 or MLKL levels were seen
(Figure 1b). Using littermates, mice were injected tail vein
with B16-F10 cells and 14 days post injection (dpi) lungs
were counted for tumor nodules. The number of tumor
nodules were reduced significantly by approximately 50%
(Figures 1c; Po0.05). Interestingly, Ripk3+/− mice showed
an intermediate phenotype between wild-type and Ripk3−/−.
Additional wild-type and Ripk3−/− mice were then injected tail
vein with B16-F10 cells and 14 dpi, after blinding, the lungs
were counted for tumor nodules. There was a 46% (±7.6%)
decrease in tumor nodules in the RIPK3 null lungs compared
with wild-type (Figures 1d; Po0.01). The size of the tumor
nodules was categorized into large, medium or small based
on width of the nodule from pictures of the lungs and although
not significant, there was a tendency toward smaller nodules
in Ripk3−/− mice (Figure 1e). To ensure the phenotype was
not restricted to B16-F10 tumor model, MC-38 colon
carcinoma cells were injected intravenously and tumor
nodules in the lung were counted 20 dpi. Consistent with
the B16-F10 tumor model, a decreased number of nodules in
the Ripk3−/− mice were found compared with wild-type mice
(Figures 1d; P= 0.14) suggesting the decrease in tumor
nodules in the Ripk3−/− was not dependent on the tumor
cell type.
Loss of RIPK1 kinase activity but not RIPK3 kinase
activity reduce tumor nodule load in the lung. The
necrosome is composed of RIPK1 and RIPK3 and the kinase
activity of RIPK1 and RIPK3 is believed to be important and/or
essential for activating necroptosis by phosphorylating MLKL.
Currently, MLKL is considered to be the essential and the only
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Figure 2 RIPK1 kinase activity but not RIPK3 kinase activity or MLKL in the tumor microenvironment is needed for tumor nodule formation in the lung. Tumor nodules were
counted 14 dpi of B16-F10 cells into (a) Wt and Ripk1K45A/K45A mice (pooled data of n= 2 experiments; 4–7 mice were used per group in each experiment) and representative
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Mlkl−/− and Ripk3−/− mice and representative pictures are shown (data from of n= 2 experiments; 2–6 mice were used per group in each experiment). (e) Paraffin-embedded
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known effector protein for necroptosis.10,11 To determine if
proteins composing the necrosome were important in the
reduction of tumor nodules in the lung, RIPK1 kinase dead
(K45A) mice were injected with B16-F10 cells (tail i.v.) and
after 14 dpi, the lungs were harvested, blinded and tumor
nodules were counted. Tumor nodules in the Ripk1K45A/K45A
mice were decreased by 38.3% (±8.5%) compared to wild-
type mice (Figures 2a; Po0.05). Next, RIPK3 kinase dead
(K51A) mice were injected tail vein with B16-F10 cells and
again, after 14 dpi, lungs were blinded and nodules were
counted in the lung. No difference in the number of tumor
nodules were found (Figure 2b). As protein levels of the kinase
dead RIPK3 K51A mutant have been shown to be decreased
because of protein instability, we assessed the levels of protein
present in lung homogenates and found the expression of the
RIPK3 mutant to be significantly decreased (Supplementary
Figure 1a).26 To control for the decreased change in
expression, we compared the Ripk3wt/K51A with the
Ripk3K51A/K51A mice. No difference in the number of tumor
nodules were formed in the lung (Figure 2c). To verify that loss
of RIPK3 kinase activity was able to block necroptosis, isolated
endothelial cells (ECs) from the lungs of Ripk3K51A/K51A mice
were tested with typical activators of necroptosis, TNF, zVAD
and/or Smac mimetics (Supplementary Figure 1b). As
expected, compared with wild-type the RIPK3-deficient and
Ripk3K51A/K51A-expressing cells were resistant to necroptosis
caused by the combination of TNF, zVAD and Smac mimetic
treatment. Interestingly, although the kinase activity of RIPK1
was required, it appeared the loss of kinase activity from
RIPK3 was not required in tumor formation in the lung. Finally,
to assess if necroptosis was indeed the reason for the
decrease in tumor nodules in the lung, we injected B16-F10
cells tail vein into wild-type, Mlkl−/− and Ripk3−/− mice. Only a
slight decrease in the number of tumor nodules was seen in
Mlkl−/− mice, whereas the reduction of tumor nodules was
seen again in Ripk3−/−mice (Figure 2d). The combined results
from the kinase dead RIPK3 and MLKL-deficient mice
suggested an alternative role for RIPK3 involving the kinase
activity of RIPK1.
As the loss of RIPK3 in Vucur et al.17 led to an increase in
caspase-8-dependent apoptosis in a TAK1 inflammatory-
driven hepatocarcinoma, we assessed for the presence of
cell death in the lung after B16-F10 cells were injected in the
mice. TUNEL staining was used to determine cell death, as
this technique will pick up both apoptosis or necrosis/
necroptosis.27 For this, lung sections of mice injected with
B16-F10 at different timepoints (0, 6 and 12 h) were analyzed
for TUNEL-positive cells. The positive control intestinal
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Figure 3 Loss of RIPK3 in the microenvironment does not alter early immune and cytokine response upon B16-F10 injection and bone marrow reconstitution shows the
stromal compartment to be responsible. (a) B16-F10 luciferase cells home to the lung in both Wt and Ripk3−/− mice measured by IVIS luminescent imaging (representative
shown, 4–5 mice per group, n= 2). (b) Cytokine levels in total lung lysates were measured by multiplex bead assay and levels of CCL-2, CXCL-1, IL-1β and TWEAK are shown
(n= 2). (c) Corresponding immune cell infiltration analysis by flow cytometry shows inflammatory monocytes (SiglecF− Ly6G−Ly6ChiCCR2+) and neutrophil granulocyte
(SiglecF−CD11b+Ly6G+) populations. Populations were pre-gated on singlets, live cells, Ter119− and CD45+ cells. (d) Tumor nodules were counted 14 dpi of B16-F10 into
CD45.1 recipient mice reconstituted with CD45.2 Wt and CD45.2 Ripk3−/− bone marrow cells (n= 3) and CD45.2 or Ripk3−/− recipient mice reconstituted with CD45.1 or
Ripk3−/− bone marrow cells (n= 2). Each dot represents a mouse; statistical analysis done by one-way ANOVA and Bonferroni post-test. ***Po0.001
RIPK1/RIPK3 promotes vascular permeability
K Hänggi et al
4
Cell Death and Disease
epithelial cells from wild-type mice injected with TNF were
stained positive for TUNEL, whereas lungs from wild-type or
Ripk3−/− mice did not stain TUNEL positive (Figure 2e). In
addition, little to no caspase-3 activity was measured in lung
homogenates of mice injected with B16-F10 at different
timepoints (Supplementary Figure 1c). This suggests the
kinase activity of RIPK3 and therefore the ability for
necroptosis to occur in the tumor microenvironment did not
alter tumor nodule formation.
Tumor cells home to the lung in both wild-type and
Ripk3−/− mice with similar immune cell infiltrates. To
determine the additional role RIPK3 may have in metastasis,
we next assessed whether the B16-F10 cells were able to
home to the lung in the Ripk3−/− mice. B16-F10 luciferase
cells were injected and monitored after injection for move-
ment to the lung over time. Equivalent luminescence was
measured between wild-type and Ripk3−/− mice within the
first 24 h (Figure 3a). This suggested the B16-F10 cells were
surviving and homing to the lung the same in the Ripk3−/−
mice compared with wild-type.
Chemokines such as C-Cmotif chemokine ligand 2 (CCL-2)
have been shown to induce signaling to recruit inflammatory
monocytes, as well as induce endothelial extravasation.28,29
To determine if RIPK3 was critical in producing pro-
inflammatory mediators to recruit myeloid infiltrates post
injection of B16-F10 cells, cytokines/chemokines were ana-
lyzed in lungs of wild-type and Ripk3−/− mice. We examined
whether chemokines/cytokines were altered in Ripk3−/− mice
compared with wild-type mice after B16-F10 injection using
lung homogenates. An increase in CCL-2, CXCL-1 and IL-1β
was seen in both wild-type andRipk3−/−mice (Figure 3b). TNF
was below the limit of detection. This suggests the ability to
produce cytokines to attract monocytes was functional in the
lung of Ripk3−/− mice. We then assessed the immune
infiltrates in the lung by flow cytometry. After 6 h post B16-
F10 injection, a significant increase in the number of
inflammatory monocytes (Ly6ChiCCR2+) were seen in
Ripk3−/− mice compared with wild-type (Figure 3c). Similarly,
CD11b+ dendritic cells increased, whereas the CD103+
dendritic cell population decreased in wild-type and Ripk3−/−
lungs after B16-F10 injection (Supplementary Figure 2).
Natural killer T cells also responded in a similar manner in
both wild-type and Ripk3−/− lungs after B16-F10 injection
(Supplementary Figure 2).
Loss of RIPK3 in the stroma affects tumor nodule
formation in the lung. To determine the potential for the
hematopoietic or stromal compartment to have a role in the
reduction in tumor nodules found in Ripk3−/− lungs, we
performed bone marrow chimeric experiments. CD45.1
recipient mice were irradiated and reconstituted with either
wild-type or RIPK3-deficient bone marrow. Only mice with
reconstitution efficiency 495% were used for B16-F10
injection (data not shown). After 14 dpi, tumor nodules in
the mice with RIPK3-deficient hematopoietic compartment
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were similar in number compared with mice with wild-type
hematopoietic compartment (Figure 3d, left panel). This
suggests that the hematopoietic compartment does not
influence the total number of tumor nodules in the lung. We
then irradiated Ripk3−/− and CD45.2 mice and reconstituted
the bone marrow with wild-type or RIPK3-deficient bone
marrow. After 14 dpi, tumor nodules were counted. In
comparison with wild-type mice reconstituted with Ripk3−/−
bone marrow, there was a decreasing amount of tumor
nodules in the Ripk3−/− mice reconstituted with wild-type
(17.6%±23) or Ripk3−/− bone marrow (38.6%±22.6),
respectively (Figure 3d, right panel). Taken together, the data
suggested that the reduction in tumor nodules in the Ripk3−/−
mice was because of the stromal compartment and not
because of the hematopoietic compartment.
RIPK3 promotes tumor cell extravasation independent of
its kinase activity. To form tumors in the lung, the tumor
cells must extravasate past the vascular endothelial barrier.
To determine if there was a tumor cell transmigration defect,
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per group; each dot represents a mouse). (b) Evans blue blood vessel permeability assay of Wt and Ripk3−/− lungs 20 h after B16-F10 tumor cell injection i.v. (pooled data of
n= 2 experiments, 4–5 mice were used per group in each experiment; each dot represents a mouse). (c) Primary lung endothelial monolayer on transwell inserts were treated
with VEGF-A164 (100 ng/ml) for 4 h and dextran-FITC permeability assay was performed. Data show relative fluorescence unit (RFU) of dextran-FITC that passed EC barrier
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we isolated CD31+ cells from the lungs of wild-type, Ripk3−/−
or Ripk3K51A/K51A mice and performed transmigration assays.
A decreased number of B16-F10 cells transmigrated through
Ripk3−/− ECs compared with wild-type or Ripk3K51A/K51A ECs
(Figure 4a). We also determined if wild-type monocytes could
facilitate increased tumor cell transmigration. Twofold more
B16-F10 cells transmigrated through wild-type endothelial
monolayer in the presence of monocytes (Figure 4a).
Strikingly, neither the addition of wild-type nor Ripk3−/−
monocytes increased the ability of B16-F10 cells to transmi-
grate through a Ripk3−/−endothelial monolayer. By contrast,
the addition of Ripk3−/− monocytes did enhance B16-F10
transmigration through wild-type endothelial monolayer.
Moreover, the Ripk3K51A/K51A ECs allowed B16-F10 cells to
transmigrate through similar to wild-type with either wild-type
or Ripk3−/− monocytes. These results support the idea that
the hematopoietic compartment does not have a role in the
loss of tumor formation in the Ripk3−/−mice similar to findings
in Figure 3d and further supports observation that the kinase
activity of RIPK3 in the ECs is not required for the ability of
tumor cells transmigrate and tumor nodules to form in the
lung (Figures 2b and c).
Cell death in primary ECs upon co-incubation of tumor
cells is independent of RIPK3 or MLKL loss. To determine
if necroptosis occurred to allow for transmigration, we
isolated CD31+ cells from the lungs of wild-type, Ripk3−/−
and Mlkl−/− mice. Primary lung EC monolayers were
incubated with either 3 × 104 or 9 × 104 B16-F10 cells. Cell
death was assessed 8 h later by flow cytometry as our in vivo
imaging suggested the tumor cells homed to the lung within
6 h (Figure 4b). B16-F10 cells were stained for identification
with the membrane dye PKH26 and were removed from the
population for cell death assessment of ECs. Cells were then
stained using Annexin V FITC and propidium iodide (PI) to
discriminate live, early apoptotic, or late apoptotic or necrotic
cells. The overall percentage of dead wild-type ECs (either
early apoptotic or late apoptotic/necrotic cells) increased by
1–3% with the increasing amount of tumor cells, whereas
Ripk3−/− or Mlkl−/− ECs only showed an increase in 1–2%
dead cells upon 9×104 tumor cell addition. However, the
percentage of late apoptotic or necrotic ECs increased upon
tumor cell addition was independent of the genotype of the
ECs. This suggested RIPK3 may have an additional role to
that of the proposed tumor cell induced necroptosis as
proposed.25
Loss of RIPK1 kinase activity or complete loss of RIPK3
alters permeability and vessel sprouting in response to
VEGF-A. Vascular permeability has been proposed as a
model for tumor metastasis where vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF) or
CCL-2 may influence permeability.30–32 Recent data show
that activation of VEGF leads to c-Src activation and change
in VE-cadherin distribution allowing for increased vascular
permeability and subsequent tumor metastasis.33 To deter-
mine if factors involved in vascular permeability was affected,
we assayed for VEGF-A, FGF-b or TWEAK in lung homo-
genates of wild-type and Ripk3−/−mice injected with B16-F10
cells. Interestingly, the loss of RIPK3 showed no increase in
VEGF-A at 6 h after B16-F10 cell injection compared with
wild-type (Figure 5a). A decrease in metalloproteinase 9
(MMP-9) was detected at 24 h after B16-F10 cell injection in
the lungs of Ripk3−/− compared with wild-type (Figure 5a).
VEGF-A and FGF-b was also detected in supernatant of
transmigration assays of either wild-type or Ripk3−/− ECs with
monocytes and tumor cells after 20 h. MMP-9 was decreased
in the supernatant of transmigration assays of Ripk3−/− ECs
compared with wild-type (Supplementary Figure 3a). These
data suggested that factors involved in vascular permeability
were present with the exception of VEGF, which was reduced
at 6 h in the lung of Ripk3−/− after B16-F10 cell injection. We
therefore assessed if pulmonary vascular permeability after
tumor injection was affected in the Ripk3−/− mice using the
Evans blue permeability assay. Evans blue dye binds to
albumin and uptake of the dye in organs is a measure of
tissue permeability. Evans blue dye was injected into wild-
type and Ripk3−/− mice 20 h post injection of B16-F10 cells.
The amount of Evans blue dye in wild-type lung homogenate
increased slightly when B16-F10 cells were injected, but no
increase in Evans blue dye was observed in Ripk3−/− mice
(Figure 5b).
To further assess the issue of vascular permeability, we
treated primary ECs for 4 h with VEGF-A164 (referred hereafter
as VEGF-A) and assayed for endothelial leakiness using
dextran-FITC. Although a significant increase in approxi-
mately 15% of dextran-FITC detected after treating wild-type
ECs with VEGF-A, there was no increase in permeability seen
in treatedRipk3−/− ECs (Figure 5c). We assessed whether the
loss of RIPK1 kinase activity altered endothelial barrier
permeability in response VEGF-A and found the loss of RIPK1
kinase activity led to no increase in endothelial permeability in
response to VEGF-A (Supplementary Figure 3b). We then
asked if pre-stimulation with VEGF-A could increase the
number of B16-F10 cells migrating through an EC barrier.
Although the number of B16-F10 cells increased by
approximately 25% for a wild-type endothelial barrier, no
increase in B16-F10 tumor cells was seen for a Ripk3−/−
endothelial barrier (Figure 5d). To determine if other functional
roles of VEGF-A were also compromised by the lack of RIPK1
or RIPK3, we assessed vessel sprouting. Interestingly, when
RIPK3 was downregulated in human umbilical vein ECs
(HUVECs), these cells showed a twofold increase in basal
vessel sprouting. Importantly, the addition of VEGF-A induced
the outgrowth of vessel sprouts in wild-type HUVECs
(siRNA control) but not in HUVECswhere RIPK3 was silenced
by siRNA (Figure 5e). Consistent with previous reports,
HUVECs did not express RIPK3 protein at high levels and
even a slight reduction in RIPK3 levels led to a difference in
VEGF-A response in vessel sprouting (Supplementary
Figure 3c). We then assessed the role of RIPK1 in vessel
sprouting and similarly found that the loss of RIPK1 by siRNA
or loss of kinase activity of RIPK1 by use of Nec-1 led to a
decrease in vessel sprouting in response to VEGF-A
compared with wild-type HUVECs (Figure 5f). Taken together,
these results show that RIPK1 or RIPK3-deficient ECs
fail to respond to tumor-induced vascular permeability or
VEGF-A-induced permeability and angiogenesis, resulting in
a defect in B16-F10 transendothelial migration.
RIPK1/RIPK3 promotes vascular permeability
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Loss of RIPK1 kinase activity and complete loss of RIPK3
in ECs dampens p38/HSP27 signaling in response to
permeability factors. To determine the potential mechanism
of how RIPK3 may affect vascular permeability, we examined
downstream signaling in response to VEGF-A, VEGF-B or
FGF-b. In response to VEGF-A, VEGF-B or FGF-b, wild-type
ECs showed an increase in phospho-p38 followed by the
downstream phosphorylation of HSP27 protein, whereas
phospho-ERK1/2 decreased in signal (Figure 6a and
Supplementary Figure 4a). The inverse status of phospho-
p38 and phospho-ERK1/2 in response to VEGF-A has been
previously shown in HUVECs where activation of p38 leads to
decreased levels of ERK1/2 activation.34 By contrast, RIPK3
null ECs stimulated with either VEGF-A, VEGF-B or FGF-b
resulted in reduced phospho-p38 activation compared with
wild-type. More strikingly, the downstream phosphorylated
protein, HSP27, was further reduced (Figure 6a and
Supplementary Figure 4a). Conversely, phosphorylated
ERK1/2 in the Ripk3−/− ECs was increased compared with
wild-type reflecting the dampened p38 activation in the RIPK3
knockouts. Interestingly, Ripk3−/− ECs without stimulation,
had an increased basal level of phospho-p38 present
compared with wild-type cells. No major differences in the
activation of p38/HSP27 between wild-type and Ripk3−/− ECs
was seen when treated with TNF (Supplementary Figure 4a
and 4b). The inhibition of RIPK1 activity by necrostatin-1
reduced HSP27 phosphorylation similarly to the loss of
RIPK3 when ECs were treated with VEGF-A (Figure 6b). To
determine if the signaling differences occurred in vivo after
tumor cell injection, we injected mice with tumor cells and
after 2, 6 and 12 h, the lungs were homogenized for protein
lysates. Consistent with our immortalized ECs, basal levels of
phospho-p38 occurred in the Ripk3−/− lungs compared with
wild-type. At 2 h, phospho-p38 was upregulated in wild-type
mice but not in Ripk3−/− mice (Figure 6c). Taken together, our
data show that RIPK3 positively regulates the activation of
p38 and HSP27 upon permeability factor treatment (VEGF-A,
VEGF-B, FGF-b) and therefore promoting permeability in the
tumor cells to metastasize (Figure 6d).
Discussion
The current dogma is that RIPK3 causes inflammation
because of the induction of necroptosis. However, our
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previous results suggest that RIPK3 may alter cytokine
release, particularly TNF in response to loss of IAPs.24 We
therefore set out to determine if RIPK3 may have a role in the
tumor microenvironment by promoting cytokine production or
causing necroptosis leading to tumor progression. Our results
show RIPK3 did not alter tumor growth of established tumors.
In addition, changes in cytokine production in Ripk3−/− mice
compared with wild-type mice after tumor injection were
minimal. The loss of kinase activity of RIPK1 and the complete
loss of RIPK3 were found to be important in the ability of the
tumor cells to form lung nodules. Surprisingly, we did not find
Ripk3K51A/K51A or Mlkl−/− mice exhibited a reduction of tumor
nodules in the lung similar to Ripk3−/− mice. Bone marrow
chimeras showed the involvement of the stromal but not the
hematopoietic compartment was critical for the loss of tumor
nodules in the lung in Ripk3−/−mice. We then found the ability
of tumor cells to transmigrate through Ripk3−/− endothelial
barrier to be deficient and that cell death in the EC layer was
independent of the genotype when tumor cells were co-
incubated. We unexpectedly found the loss of RIPK3 or the
kinase activity of RIPK1 in the endothelial compartment were
defective in p38/HSP27 signaling in response to permeability
factors such as VEGF-A. This lack of response resulted in
decreased permeability and vessel sprouting in response to
VEGF-A. These results suggest the role of the necrosome is
minimal in the extravasation process of tumor cells and
presents a novel role for RIPK3 as a signaling platform
downstream of angiogenic factors such as VEGF and FGF.
The current difficulty in assessing the role of necroptosis in
related pathologies of human inflammatory disease is the
absence of identifying markers. The use of RIPK3 genetic
deletion, pharmacological inhibition of RIPK1 and/or correla-
tive evidence of RIPK3 protein or RNA upregulation has been
used to associate the disease state with necroptosis.35,36
However, as RIPK1 has been shown to have alternative
function in regulating apoptosis and necroptosis37–39 and also
directly influencing inflammation,24,40,41 further downstream
effectors of necroptosis such as the use of Mlkl−/− mice are
required to prove the role of necroptosis.42 In our experiments,
the number of pulmonary tumor nodules in the Mlkl−/− mice
were slightly reduced compared with wild-type mice but not to
the same extent as in theRipk3−/−mice. It is unclear what may
be the reason for the difference in the tumor nodule numbers in
the MLKL knock-out mice we obtained compared with Strilic
et al.25, except for the source of the MLKL null mice. Our data
also show that the kinase activity of RIPK1 has a role in the
ability of tumor nodules to form in the lung. Activation of
VEGFR2 by VEGF-A or VEGF-B causes phosphorylation of
c-Src and has been linked to increased permeability by
altering adherens junction formation, VE-cadherin.33,43 c-Src
has been shown to inhibit Fas-induced caspase-8 activation
by phosphorylation at Tyr380.44 Further studies are required to
determine if RIPK1 and RIPK3 alter tumor cell extravasation
as a complex with or without caspase-8 involvement or if these
proteins regulate different pathways to result in vascular
permeability.
Vascular permeability requires tissue remodeling similar to
wound healing. Impaired wound healing was found inRipk3−/−
mice compared with wild-type mice, characterized by a
decreased MMP-9 protein expression and delayed CD31+
staining and VEGF production.45 Of the cytokines and growth
factors we assayed, only MMP-9 was reduced at 24 h in the
Ripk3−/− mice compared with wild-type upon tumor cell
injection. The decrease in MMP-9 protein levels correspond
to an increase in neutrophil infiltration of the lung at 24 h in the
Ripk3−/−, suggesting an attempt of the immune system to
compensate for the lack of response in the endothelial
compartment. The ability of Ripk3−/− monocytes to enhance
transmigration of tumor cells through a wild-type endothelial
layer further suggests a defect in the Ripk3−/− ECs to respond
to extracellular cues. Indeed, the absence of RIPK3 reduced
signaling in response to VEGF-A, VEGF-B and FGF-b but not
TNF in the p38/HSP27 pathway, a key pathway in perme-
ability. Our results show that the reduced tumor nodule
formation in RIPK3-deficient mice cannot be attributed to the
failure to respond to one stimuli alone. Interestingly, in Seifert
et al.22, the loss of Mincle combined with the V12K-Ras PDA
did not protect, as well as the loss of RIPK3, suggesting
additional factors may have a role in the ability of RIPK3 to
form PDA in a V12K-Ras model. Alternatively, the role of
RIPK3 may be more prevalent in tissues that re-model
frequently or tissues that must function as a barrier for
infection. Further investigation of other permeability factors
in vivo and whether these ligands can form complexes of
RIPK1/RIPK3 will be of interest to determine if these
intracellular proteins can be targeted to block several path-
ways involved in tumor metastasis.
Ripk3−/−mice have not been reported to have any vascular
defects during normal development. Interestingly, we repeat-
edly detect increased basal phospho-p38 levels in untreated
immortalized ECs and lung homogenates suggesting the loss
of RIPK3 is compensated during development and regular
homeostasis. It appears only during stress such as wound
healing or tumor challenge, does RIPK3 become required for
the response to the additional stimuli. Changes at the basal
level in structure of the vessels or lung vessel structure
have not been assessed and may provide insight to why the
Ripk3−/− mice develop with little to no overt phenotype.
In summary, our study shows the kinase activity of RIPK1
and RIPK3 has a physiological role in the tumor microenviron-
ment, in particular tumor cell extravasation and remodeling by
altering the downstream signaling pathways of permeability
factors. This is a novel role for the kinase activity of RIPK1/
RIPK3 in addition to its role in regulating necroptosis. In the
context of inflammation and cell death, this supports previous
reports suggesting the loss of kinase activity of RIPK1 or the
complete loss of RIPK3 cannot be used as an indicator of
necroptosis and the potential of RIPK1/RIPK3 to be a
signaling platform will need to be assessed in each disease
model individually.
Materials and Methods
Animal work. Animals were maintained under optimized hygiene conditions
(OHB), and experiments were approved by Zürich Cantonal Veterinary Committee in
accordance to the guidelines of the Swiss Animal Protection Law (License 119/2012
and 186/2015). C57BL/6 mice were purchased from Janvier Labs (France),
Ripk3−/− mice were a kind gift from V Dixit,46 SNP analyzed at N= 7, Ripk1K45A/K45A,
Ripk3K51A/K51A mice were a kind gift from John Bertin and Peter J Gough from
GlaxoSmithKline (PA, USA),26,40 Mlkl−/− mice were obtained from J
Murphy and W Alexander10 (WEHI, Melbourne, Australia). Mice were injected with
B16-F10 (2 × 105 cells) or MC-38 (3 × 105 cells) intravenously in 200 μl PBS or
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subcutaneous in 100 μl PBS (1 × 105). Mice were killed at indicated timepoints by
overdose (ketamin/xylazin cocktail), lungs perfused and blinded before further
processing (nodule counting, flow cytometric analysis). For bone marrow chimeric
experiments, Wt CD45.1 or Ripk3−/− mice were irradiated two times at 550 rads, 6 h
apart, injected with donor bone marrow and assessed for reconstitution efficiency at
6 weeks. Only mice with reconstitution efficiency 495% were used for further
experiments.
Cell culture. MC-38 and B16-F10 cells were cultured at maximum 50%
confluence in Dulbecco’s modified Eagle's medium (Gibco, ThemoFisher Scientific,
Germany) with high glucose (4.5 g/l) supplemented with 10% fetal bovine serum
(FBS; Gibco, ThemoFisher Scientific) and penicillin/streptomycin/glutamine (Gibco,
ThemoFisher Scientific). Primary- and SV40 immortalized lung ECs and HUVECs
(C-12200, Promocell, Germany) were cultured in EBM-2 media supplemented with
EGM according to the manufacturers recommendation (Lonza, Germany).
Primary lung EC isolation. Lungs were perfused with PBS and HBSS
(+Collagenase 1 mg/ml; Sigma Aldrich, Switzerland) and minced before incubation
with HBSS(+Collagenase) for 45 min and further processed for antibody incubation.
Mouse lung cell suspension was incubated with anti-CD31(eBioscience, Austria, clone
390) antibody for 30 min in PBS (0.5% BSA) at 1 : 20 dilution in order to isolate lung
ECs. To isolate monocytes from bone marrow cell suspension, the anti-CD115-biotin
(eBioscience, clone AFS98) antibody was used at dilution of 1 : 50 in HBSS+2% FBS.
Cell suspensions were incubated in primary antibody for 30 min at 4 °C followed by
incubation with anti-rat IgG or streptavidin magnetic particles and sorted on LS
columns according to the manufacturers recommendations (Miltenyi, Switzerland).
Transendothelial migration assay. EC populations 485% purity for
CD31+ cells were used. In all, 3 × 104 primary ECs were seeded 5–8 days after
isolation on a gelatin coated insert (Corning, Netherlands, 8 μm pore size) in EBM-2
(Lonza). Two days after seeding, cell culture media was changed RPMI (Gibco) in
bottom well (3% FBS) and insert (1% FBS) with or without pre-treatement of VEGF
(100 μg/ml) for 4 or 1 h before addition of 2 × 104 PKH26+ (Sigma Aldrich)
membrane stained B16-F10 tumor cells and/or 1 × 105 primary isolated monocytes
(CD115+). After 20 h, the remaining cells inside the insert were removed,
membrane fixed in 2% PFA and mounted using slow fade gold with dapi
(Thermoscience Fisher, Germany). Microscopic fluorescence picture were taken at
× 10 magnification using ZEISS AXIO Scan Z.1 Centre for Microscopy and Image
Analysis (ZMB), Switzerland. PKH26+ cells were counted per field of view. A
minimum of 10–17 field of views were counted per transwell.
Dextran-FITC permeability assay. In all, 3 × 104 primary ECs were
seeded 5–8 days after isolation on a gelatin-coated insert (Corning, 8 μm pore size)
in EBM-2 (Lonza) and grown to confluent monolayer for 3 days. Cells were then pre-
treated with VEGF-A164 for 4 h before dextran-FITC was added into insert at final
concentration of 1 mg/ml. Supernatant from bottom well was collected 1 h after
addition of dextran-FITC and fluorescence intensity was measured by TECAN
Infinite 200 Pro multireader (Switzerland) using λEx= 485 nm and λEm= 525 nm.
Relative fluorescence unit was quantified.
HUVEC sprouting assay. HUVECs were transfected with Oligofectamine
Reagent (Invitrogen, Germany) with 200 nM siRNA universal negative control
(SIC001, Sigma Aldrich) or siRNA against RIPK1 (sense 5′-CCACUAGUCUGAC
GGAUAA[dT][dT]-3′) or RIPK3 (sense 5′-CCAGAGACCUCAACUUUCA[dT][dT]-3′).
After 2 days, transfected cells were coated on cytodex beads and embedded on a
fibrinogen gel. Cells were treated with or without VEGF (50 ng/ml) and/or Nec-1
(S8037, Abscource Diagnostics GmbH, Germany, 25 μM) for 24 h. After treatment,
cells were fixed (4%PFA for 30 min), permeabilized (0.2%Triton X-100 in PBS for
10 min) and stained with phalloidin (1 μg/ml in PBS, P1951 Sigma Aldrich) for 1 h.
Images were obtained with a Zeiss LSM 510 META confocal microscope (Germany)
(10x) and quantification was done with ImageJ.
Cytokine measurement. Cell culture supernatant and lung lysates were
prepared according to the manufacturer's instructions. Multiplex cytokine kits from
eBioscience/Affymetrix (Austria) and BioTechne (UK) were used. The measure-
ments were performed on Bio-Plex 200 system (Bio-Rad Laboratories, Switzerland)
and data were analyzed by Bio-Plex software 6.0.
Immunohistochemistry. Organs were fixed in 4% paraformaldehyde,
paraffin embedded and 4 μm sections were stained for TUNEL according to the
manufacturer recommendation (Biotool, Germany). Heat-induced epitope retrieval
with citrate buffer, blocked in 3% goat serum, permeabilized with 0.3% Triton X-100
and stained with cleaved caspase-3 (Cell Signaling Technology, MA, USA) or
TUNEL. Microscopic fluorescence picture were taken at indicated magnification
using ZEISS AXIO Scan Z.1 (10x and 20x) microscope.
Antibodies. Flow cytometry analysis was performed according to standard
procedure and the following antibodies were purchased from eBioscience unless
noted otherwise. The following antibodies were used: CD45.1-eFluor 450, CD45.2-
APC-Cy7, CD45-brilliant violet 605, CD11b-PE-Cy7, Ly6C-brilliant violet 711,
CD11c-brilliant violet 510, Ly6G-PerCP-Cy5.5, MHC-II-alexa fluor 700, CD103-
FITC, SiglecF-brilliant violet 421, CD86-brilliant violet 650, Ter119-brilliant violet 421,
CCR-2-APC (BioTechne), fixable live/dead eFluor 780 or PI for live/dead assays.
For immunoblotting, antibodies were diluted at recommended dilution in 5% skim
milk in PBS (0.1% Tween). The following antibodies were used: RIPK3 (BioTechne),
phospho-p38, total p38, phospho-ERK1/2, total ERK1/2, phospho-HSP27 (clone
D1H2) from Cell Signaling Technology, beta-actin (clone AC-15, Sigma Aldrich),
HSP70 (clone 3A3 Santa Cruz Biotechnology, CA, USA), secondary anti-rat IgG
and anti-mouse IgG (Southern Biotec).
Statistics. N refers to the number of independent experiments performed. For
each experiment, 3–8 mice were used per group. Every dot shown in the graphs
represents an individual mouse. GraphPad Prism (GraphPad Software, CA, USA)
was used for statistical analyses. All P-values were calculated by either t-test or
one-way ANOVA as indicated in the corresponding figure legend and indicated as
asterisks (*P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001).
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